AI Summary
Thinking
Thinking
We reviewed 59 live results for amgevita yuflyma hyrimoz adalimumab biosimilars and narrowed them down to the 3 options that look most worth comparing first.
The options are Amgevita / Yuflyma / Hyrimoz (Adalimumab Biosimilars), Amgevita (adalimumab) and Yuflyma (Adalimumab).
Source: Amgevita
Description
A group of TNF inhibitor monoclonal antibody biosimilars recently approved in Singapore. These are indicated for managing conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
Best for
rheumatoid arthritis patients, Crohn’s disease treatment, psoriatic arthritis care and ulcerative colitis management
Rate this product
Source: Amgen Inc.
Description
Amgevita is the international brand name for Amgen's adalimumab biosimilar, widely used in Canada, Europe, and New Zealand. It is indicated for the treatment of autoimmune diseases such as Hidradenitis Suppurativa, Uveitis, and juvenile idiopathic arthritis, alongside major inflammatory conditions. The product is available in convenient formats including single-use pre-filled pens and syringes.
Best for
international patients, uveitis treatment, hidradenitis suppurativa care and ankylosing spondylitis patients
Rate this product
Source: Celltrion Healthcare
Description
Yuflyma is an adalimumab biosimilar, classified as a biologic Disease-Modifying Antirheumatic Drug (DMARD). It is used to treat immune-mediated inflammatory diseases by targeting and neutralizing TNF-alpha, helping to alleviate symptoms in conditions like psoriasis and arthritis.
Best for
psoriatic arthritis, inflammatory disease management and biologic DMARD users
Rate this product
| Compare | #1Amgevita / Yuflyma / Hyrimoz (Adalimumab Biosimilars) | #2Amgevita (adalimumab) | #3Yuflyma (Adalimumab) |
|---|---|---|---|
| Source | Amgevita | Amgen Inc. | Celltrion Healthcare |
| Description | A group of TNF inhibitor monoclonal antibody biosimilars recently approved in Singapore. These are indicated for managing conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. | Amgevita is the international brand name for Amgen's adalimumab biosimilar, widely used in Canada, Europe, and New Zealand. It is indicated for the treatment of autoimmune diseases such as Hidradenitis Suppurativa, Uveitis, and juvenile idiopathic arthritis, alongside major inflammatory conditions. The product is available in convenient formats including single-use pre-filled pens and syringes. | Yuflyma is an adalimumab biosimilar, classified as a biologic Disease-Modifying Antirheumatic Drug (DMARD). It is used to treat immune-mediated inflammatory diseases by targeting and neutralizing TNF-alpha, helping to alleviate symptoms in conditions like psoriasis and arthritis. |
| Best for | rheumatoid arthritis patients, Crohn’s disease treatment, psoriatic arthritis care and ulcerative colitis management | international patients, uveitis treatment, hidradenitis suppurativa care and ankylosing spondylitis patients | psoriatic arthritis, inflammatory disease management and biologic DMARD users |
| Action | Amgevita | Amgen Inc. | Celltrion Healthcare |
| Rate this product |
"Amgevita / Yuflyma / Hyrimoz (Adalimumab Biosimilars) from Amgevita."
TopFind picked this because Offers modern biologic therapy options for several inflammatory conditions with recent HSA approval for biosimilar use.
Note: TopFind AI compiles product and service information for general comparison purposes only.